Meta Pixel

News and Announcements

Dealing with Investor Silence: How to Navigate the Quiet Phase of Capital Raising

  • Published June 21, 2023 11:00PM UTC
  • Publisher Wholesale Investor
  • Categories Capital Raising Tips

Are you familiar with the feeling of being left in the dark when an investor suddenly goes quiet? It’s an all too common scenario during the capital raising process, leaving founders uncertain and wondering what went wrong. But fear not, because in this insightful video, we provide valuable advice on how to effectively manage yourself when faced with investor silence.

YouTube player

Ghosting can be frustrating and disheartening, especially after receiving positive signals from an investor. However, it’s important to remember that silence doesn’t necessarily indicate rejection or failure. In this video, we dive into strategies and mindset shifts that will empower you to navigate this quiet phase with confidence and resilience.

Discover practical tips on how to maintain your composure and take control of the situation when investors suddenly go silent. We’ll discuss the importance of self-management during these challenging moments, helping you maintain focus on your goals and move forward with your capital raising efforts.

Don’t let investor silence derail your progress. Instead, leverage this opportunity to fine-tune your approach, reassess your communication strategies, and explore alternative avenues for engagement. By watching this video, you’ll gain valuable insights that will equip you with the tools and mindset needed to overcome the challenges of investor silence and continue on your path towards successful capital raising.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now